
With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced...
Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome...
-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome-- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in...
-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren...
NEW YORK, April 12 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Thursday, April 13, 2006 on the following Nasdaq Stock Market and New York Stock...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.55 | -3.83542538354 | 14.34 | 14.42 | 13.06 | 444987 | 13.71336581 | DE |
4 | 1.94 | 16.3713080169 | 11.85 | 14.83 | 10.9 | 590798 | 13.3003928 | DE |
12 | -2.82 | -16.9777242625 | 16.61 | 16.65 | 10.9 | 559366 | 13.00997248 | DE |
26 | -1.25 | -8.31117021277 | 15.04 | 170.09 | 10.9 | 552380 | 13.86245126 | DE |
52 | -8.76 | -38.8470066519 | 22.55 | 170.09 | 10.9 | 514161 | 16.73031188 | DE |
156 | 9.57 | 226.777251185 | 4.22 | 170.09 | 3.33 | 467089 | 13.29486312 | DE |
260 | 10.86 | 370.648464164 | 2.93 | 170.09 | 0.965 | 352432 | 11.00705248 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.